Filtered By:
Specialty: Transplant Surgery
Procedure: Lung Transplant
This page shows you your search results in order of date. This is page number 15.
Order by Relevance | Date
Total 238 results found since Jan 2013.
Driveline Infection Is Not Associated With Increased Risk of Thrombotic Events in CF-LVAD Patients
It has been debated whether anti-thrombotic therapy should be adjusted in the setting of driveline infection (DLI) as infection may lead to a pro-inflammatory state associated with platelet activation and increased risk of thrombotic complications. The aim of this study was to examine the relationship of DLI and thrombotic complications, notably stroke and device thrombosis (DT), in patients with continuous-flow LVADs.
Source: The Journal of Heart and Lung Transplantation - April 1, 2015 Category: Transplant Surgery Authors: J. Fried, B. Cagliostro, A. Levin, O. Wever-Pinzon, A.R. Garan, R. Te-Frey, K.O. Ronquillo, K. Takeda, H. Takayama, M. Yuzefpolskaya, D.M. Mancini, Y. Naka, P.C. Colombo, V. Topkara Source Type: research
First Implantation in Man of a New Magnetically Levitated Left Ventricular Assist Device (HeartMate III)
Outcomes of heart failure patients supported by a continuous flow left ventricular assist device (LVAD) have steadily improved over the past decade due in large part to better patient selection and management 1,2. Nevertheless, adverse events such as bleeding, infection, stroke and thrombus persist and limit the overall effectiveness of this therapy. Bleeding is the most common serious adverse event that results from the extensive surgery required for implantation and blood component damage due to shear forces in the small blood flow paths of current design axial-flow and centrifugal-flow pumps.
Source: The Journal of Heart and Lung Transplantation - March 7, 2015 Category: Transplant Surgery Authors: Jan D. Schmitto, Jasmin S. Hanke, Sebastian V. Rojas, Murat Avsar, Axel Haverich Source Type: research
Left Ventricular Assist Device Thrombosis In The Setting of Left Ventricular Recovery
Left ventricular assist device (LVAD) thrombosis has become increasingly recognized as a complication of mechanical circulatory support.1,2 Morbidity, including increased rate of stroke, and a marked increase in mortality are seen with LVAD thrombosis.1
Source: The Journal of Heart and Lung Transplantation - December 23, 2014 Category: Transplant Surgery Authors: Thomas E. Hurst, Nader Moazami, Randall C. Starling Source Type: research
Blood pressure and stroke risk in left ventricular assist devices
Ischemic and hemorrhagic stroke are one of the most devastating outcomes arising from treatment of end-stage congestive heart failure with a left ventricular assist device (LVAD)1. Stroke after LVAD is associated with increased risk of mortality and is a leading cause of not qualifying for transplantation. The risk of stroke is one of many factors limiting more widespread adoption of this technology for end-stage heart failure. The risk factors for stroke in LVAD have been the subject of several studies, with recent infection2 and changes in anti-thrombotics being commonly found3.
Source: The Journal of Heart and Lung Transplantation - December 5, 2014 Category: Transplant Surgery Authors: Joshua Z. Willey Source Type: research
Systolic Blood Pressure on Discharge after Left Ventricular Assist Device Insertion is Associated with Subsequent Stroke
Stroke is a significant complication in patients supported with continuous-flow left ventricular assist devices (CF-LVAD) and hypertension (HTN) is a significant risk factor for stroke, but the association between blood pressure and stroke in LVAD patients is not well characterized.
Source: The Journal of Heart and Lung Transplantation - October 22, 2014 Category: Transplant Surgery Authors: Michael E. Nassif, Anjan Tibrewala, David S. Raymer, Adam Andruska, Eric Novak, Justin M. Vader, Akinobu Itoh, Scott C. Silvestry, Gregory A. Ewald, Shane J. LaRue Source Type: research
Early power elevations and adverse events with the HeartMate II left ventricular assist device: An unsettled issue
In a recent issue of this journal, Salerno et al1 evaluated the prevalence and potential impact of early power elevation (PEL) events (power ≥10 W in the first 14 days after implant) on future adverse outcomes, including mortality, hemorrhagic and ischemic stroke, hemolysis and pump thrombosis, among 138 patients requiring implantation of a HeartMate II left ventricular assist device (LVAD). Patients with a PEL (20%) had similar survival, complications rates and late power elevations compared with patients without a PEL.
Source: The Journal of Heart and Lung Transplantation - September 10, 2014 Category: Transplant Surgery Authors: Omar Wever-Pinzon, Ulrich P. Jorde Tags: Case Anecdotes, Comments and Opinions Source Type: research
Inadequate Venous Return As A Primary Cause For Fontan Circulatory Limitation
The Fontan procedure is an approach to single ventricle palliation involving connection of systemic veins to the pulmonary artery(PA) without a functional sub-pulmonary pumping chamber. This is associated with chronically elevated systemic venous pressure and limited stroke volume augmentation. The latter is usually attributed to either inability to increase transpulmonary flow related to abnormal pulmonary vascular response in the absence of a sub-pulmonary ventricle or to low ventricular compliance.
Source: The Journal of Heart and Lung Transplantation - July 15, 2014 Category: Transplant Surgery Authors: Alexander R. Opotowsky, Dan Halpern, Thomas J. Kulik, David M. Systrom, Fred Wu Source Type: research
Inadequate venous return as a primary cause for Fontan circulatory limitation
The Fontan procedure is an approach to single-ventricle palliation involving the connection of systemic veins to the pulmonary artery (PA) without a functional sub-pulmonary pumping chamber. This is associated with chronically elevated systemic venous pressure and limited stroke volume augmentation. The latter is usually attributed to either inability to increase transpulmonary flow related to abnormal pulmonary vascular response in the absence of a sub-pulmonary ventricle or to low ventricular compliance.
Source: The Journal of Heart and Lung Transplantation - July 15, 2014 Category: Transplant Surgery Authors: Alexander R. Opotowsky, Dan Halpern, Thomas J. Kulik, David M. Systrom, Fred Wu Tags: Case Anecdotes, Comments and Opinions Source Type: research
Cerebrovascular disease in the era of left ventricular assist devices with continuous flow: Risk factors, diagnosis and treatment
Cerebral infarction and hemorrhage are among the principal sources of morbidity and mortality associated with mechanical circulatory support. There has been particular concern with the recently reported increased rate of device thrombosis in continuous-flow left ventricular assist devices. The neurologic management of stroke among these patients has limited data to inform current clinical practices. In this investigation we review the available literature on stroke in patients with continuous-flow left ventricular assist devices, with a focus on treatment algorithms in the acute setting and for secondary stroke prevention.
Source: The Journal of Heart and Lung Transplantation - May 31, 2014 Category: Transplant Surgery Authors: Joshua Z. Willey, Ryan T. Demmer, Hiroo Takayama, Paolo C. Colombo, Ronald M. Lazar Source Type: research
Pump size of Berlin Heart EXCOR pediatric device influences clinical outcome in children
Conclusions: The broad range of body sizes in children from newborns to adolescents requires a wide choice of appropriately sized devices. Large pump size in relation to BSA is an independent risk factor for occurrence of thromboembolic events.
Source: The Journal of Heart and Lung Transplantation - April 21, 2014 Category: Transplant Surgery Authors: Oliver Miera, Katharina R.L. Schmitt, Eva Delmo-Walter, Stanislav Ovroutski, Roland Hetzer, Felix Berger Tags: Original Clinical Science Source Type: research
Extracorporeal Membrane Oxygenation: Experience In Acute Graft Failure After Heart Transplantation
ConclusionTemporary ECMO support for postoperative output failure is an acceptable option as a last resort for otherwise doomed patients with fatal graft failure after HTx. The small fraction of patients surviving, appear to have a decent long‐term prognosis.This article is protected by copyright. All rights reserved.
Source: Clinical Transplantation - April 1, 2014 Category: Transplant Surgery Authors: Sven Lehmann, Madlen Uhlemann, Christian D. Etz, Jens Garbade, Thomas Schroeder, Michael Borger, Martin Misfeld, Hartmuth B Bittner, Friedrich Wilhelm Mohr Tags: Original Article Source Type: research
Post-approval study of a highly pulsed, low-shear-rate, continuous-flow, left ventricular assist device, EVAHEART: A Japanese multicenter study using J-MACS
Conclusions: The EVAHEART device provides safe, reliable and long-term circulatory support with improved survival in commercial settings of BTT in Japan, where the transplant waiting period is much longer. Incidences of GI bleeding, hemolysis, right ventricular failure, device thrombosis and mechanical failure were extremely rare in patients on EVAHEART devices.
Source: The Journal of Heart and Lung Transplantation - March 6, 2014 Category: Transplant Surgery Authors: Satoshi Saito, Kenji Yamazaki, Tomohiro Nishinaka, Yuki Ichihara, Minoru Ono, Syunei Kyo, Takashi Nishimura, Takeshi Nakatani, Koichi Toda, Yoshiki Sawa, Ryuji Tominaga, Tadahisa Tanoue, Yoshikatsu Saiki, Yoshiro Matsui, Takahiro Takemura, Hiroshi Niinami Tags: Featured Articles Source Type: research
Early elevations in pump power with the HeartMate II left ventricular assist device do not predict late adverse events
Background: The aim of this study was to evaluate the prevalence of early pump power elevation events in patients with the HeartMate II (HMII) and its impact on subsequent development of stroke and pump thrombosis.Methods: We analyzed>45,000 measurements of pump power and pump speed measured during the initial hospitalization period and>12,000 follow-up measurements obtained from 138 consecutive patients implanted with a HMII between January 2009 and December 2012. An early power elevation (PEL) event was defined as power ≥10 W within the first 14 post-operative days. Patients were divided into two groups: those with an ...
Source: The Journal of Heart and Lung Transplantation - March 3, 2014 Category: Transplant Surgery Authors: Christopher T. Salerno, Kartik S. Sundareswaran, Thomas P. Schleeter, Sina L. Moanie, David J. Farrar, Mary Norine Walsh Tags: Featured Articles Source Type: research
Association between cell-derived microparticles and adverse events in patients with nonpulsatile left ventricular assist devices
Background: Continuous-flow left ventricular assist devices (LVADs) expose blood cells to high shear stress, potentially resulting in the production of microparticles that express phosphatidylserine (PS+) and promote coagulation and inflammation. In this prospective study, we attempted to determine whether PS+ microparticle levels correlate with clinical outcomes in LVAD-supported patients.Methods: We enrolled 20 patients undergoing implantation of the HeartMate II LVAD (Thoratec Corp, Pleasanton, CA) and 10 healthy controls who provided reference values for the microparticle assays. Plasma was collected before LVAD implan...
Source: The Journal of Heart and Lung Transplantation - January 21, 2014 Category: Transplant Surgery Authors: Angelo Nascimbene, Ruben Hernandez, Joggy K. George, Anita Parker, Angela L. Bergeron, Subhashree Pradhan, K. Vinod Vijayan, Andrew Civitello, Leo Simpson, Maria Nawrot, Vei-Vei Lee, Hari R. Mallidi, Reynolds M. Delgado, Jing Fei Dong, O.H. Frazier Tags: Featured Articles Source Type: research
